203 related articles for article (PubMed ID: 26864917)
1. Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening.
Zhang W; Zhai L; Lu W; Boohaker RJ; Padmalayam I; Li Y
Chem Biol Drug Des; 2016 Aug; 88(2):178-87. PubMed ID: 26864917
[TBL] [Abstract][Full Text] [Related]
2. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.
Nagarajan S; Skoufias DA; Kozielski F; Pae AN
J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208
[TBL] [Abstract][Full Text] [Related]
3. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.
Maliga Z; Kapoor TM; Mitchison TJ
Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373
[TBL] [Abstract][Full Text] [Related]
4. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
[TBL] [Abstract][Full Text] [Related]
5. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
[TBL] [Abstract][Full Text] [Related]
6. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
7. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
[TBL] [Abstract][Full Text] [Related]
8. A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor.
Ding S; Nishizawa K; Kobayashi T; Oishi S; Lv J; Fujii N; Ogawa O; Nishiyama H
J Urol; 2010 Sep; 184(3):1175-81. PubMed ID: 20663523
[TBL] [Abstract][Full Text] [Related]
9. Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.
El-Nassan HB
Eur J Med Chem; 2013 Apr; 62():614-31. PubMed ID: 23434636
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic monastrol derivatives as adjective inhibitors of drug-resistant Eg5: a molecular dynamics perspective.
Shahabipour S; Shamkhali AN; Razzaghi-Asl N
J Biomol Struct Dyn; 2024 Mar; ():1-14. PubMed ID: 38450658
[TBL] [Abstract][Full Text] [Related]
11. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.
Makala H; Ulaganathan V
J Recept Signal Transduct Res; 2018 Feb; 38(1):12-19. PubMed ID: 29041840
[TBL] [Abstract][Full Text] [Related]
13. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
Xing ND; Ding ST; Saito R; Nishizawa K; Kobayashi T; Inoue T; Oishi S; Fujii N; Lv JJ; Ogawa O; Nishiyama H
Asian J Androl; 2011 Mar; 13(2):236-41. PubMed ID: 21297652
[TBL] [Abstract][Full Text] [Related]
14. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
Peters T; Lindenmaier H; Haefeli WE; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):291-9. PubMed ID: 16365780
[TBL] [Abstract][Full Text] [Related]
15. Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5.
Sun XD; Shi XJ; Sun XO; Luo YG; Wu XJ; Yao CF; Yu HY; Li DW; Liu M; Zhou J
Acta Pharmacol Sin; 2011 Dec; 32(12):1543-8. PubMed ID: 21986572
[TBL] [Abstract][Full Text] [Related]
16. The discovery of tetrahydro-beta-carbolines as inhibitors of the kinesin Eg5.
Barsanti PA; Wang W; Ni ZJ; Duhl D; Brammeier N; Martin E; Bussiere D; Walter AO
Bioorg Med Chem Lett; 2010 Jan; 20(1):157-60. PubMed ID: 19945875
[TBL] [Abstract][Full Text] [Related]
17. New chemical tools for investigating human mitotic kinesin Eg5.
Klein E; DeBonis S; Thiede B; Skoufias DA; Kozielski F; Lebeau L
Bioorg Med Chem; 2007 Oct; 15(19):6474-88. PubMed ID: 17587586
[TBL] [Abstract][Full Text] [Related]
18. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
Debonis S; Skoufias DA; Indorato RL; Liger F; Marquet B; Laggner C; Joseph B; Kozielski F
J Med Chem; 2008 Mar; 51(5):1115-25. PubMed ID: 18266314
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5.
Yokoyama H; Sawada J; Katoh S; Matsuno K; Ogo N; Ishikawa Y; Hashimoto H; Fujii S; Asai A
ACS Chem Biol; 2015 Apr; 10(4):1128-36. PubMed ID: 25622007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
